Trials / Completed
CompletedNCT00077779
Adalimumab for the Induction and Maintenance of Clinical Remission in Subjects With Crohn's Disease
A Multi-Center Randomized, Double-Blind, Placebo-Controlled Study of the Human Anti-TNF Monoclonal Antibody Adalimumab for the Induction and Maintenance of Clinical Remission in Subjects With Crohn's Disease
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 854 (actual)
- Sponsor
- Abbott · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to test whether Adalimumab (at two different doses) can induce and maintain clinical remission in subjects with active Crohn's disease when compared to placebo (a substance containing no medication)
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Adalimumab |
Timeline
- Start date
- 2003-07-01
- First posted
- 2004-02-16
- Last updated
- 2007-09-26
Locations
43 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00077779. Inclusion in this directory is not an endorsement.